WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Bio Basic Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact, Medical
Nimble Therapeutics | December 14, 2022
Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company. For each program, Nimble has delivered lead compounds ready for further pre-clinical testing and subsequent IND studies. As with all its partnered research programs, Nimble remains eligible for additional future pre-clinical, clinical, and commercial milestones, and royalties attached to each program as development progresses....
Cell and Gene Therapy
SOPHiA GENETICS | March 08, 2022
SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair ...
Genprex, Inc. | December 16, 2022
Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...
Discovery Life Sciences | October 28, 2020
Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE